213 related articles for article (PubMed ID: 31129580)
21. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI
Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
Yan LZ; Herrington JD
J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
[TBL] [Abstract][Full Text] [Related]
23. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
24. Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children.
Molloy L; Abdulhamid I; Srivastava R; Ang JY
Pediatr Infect Dis J; 2020 May; 39(5):419-420. PubMed ID: 32032173
[TBL] [Abstract][Full Text] [Related]
25. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.
Zhao Y; Lin Q; Liu L; Ma R; Chen J; Shen Y; Zhu G; Jiang E; Mi Y; Han M; Wang J; Feng S
Clin Infect Dis; 2020 Dec; 71(Suppl 4):S386-S393. PubMed ID: 33367574
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Clin Microbiol Infect; 2005 May; 11(5):415-8. PubMed ID: 15819873
[TBL] [Abstract][Full Text] [Related]
27. Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
Tan SH; Teng CB; Ng TM; Lye DC
Ann Acad Med Singap; 2014 Nov; 43(11):526-34. PubMed ID: 25523856
[TBL] [Abstract][Full Text] [Related]
28. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
[TBL] [Abstract][Full Text] [Related]
29.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
30. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.
Chumbita M; Puerta-Alcalde P; Yáñez L; Angeles Cuesta M; Chinea A; Español-Morales I; Fernandez-Abellán P; Gudiol C; González-Sierra P; Rojas R; Sánchez-Pina JM; Vadillo IS; Sánchez M; Varela R; Vázquez L; Guerreiro M; Monzo P; Lopera C; Aiello TF; Peyrony O; Soriano A; Garcia-Vidal C
Microbiol Spectr; 2023 Aug; 11(4):e0067423. PubMed ID: 37367629
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in
Kang JS; Moon C; Mun SJ; Lee JE; Lee SO; Lee S; Lee SH
J Korean Med Sci; 2021 Nov; 36(43):e273. PubMed ID: 34751008
[TBL] [Abstract][Full Text] [Related]
32. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
33. Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome.
Krcméry V; Trupl J; Kunová A; Spánik S; Ilavská I; Hel'pianska L; Bezáková I; Drgona L; Oravcová E; Studená M; Lacka J; Sevcíková L; Koren P; Kukucková E; Stopková K; Krupová I; Grausová S; Svec J
Bratisl Lek Listy; 1996 Nov; 97(11):647-51. PubMed ID: 9117427
[TBL] [Abstract][Full Text] [Related]
34. Real life experience with ceftolozane/tazobactam therapy for
Khan S; Phe K; Tam VH
J Chemother; 2021 Dec; 33(8):595-597. PubMed ID: 33645440
[No Abstract] [Full Text] [Related]
35. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Maraolo AE; Cascella M; Corcione S; Cuomo A; Nappa S; Borgia G; De Rosa FG; Gentile I
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):861-871. PubMed ID: 28803496
[TBL] [Abstract][Full Text] [Related]
36. Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.
Monterrubio-Villar J; Rodríguez-Garrido S; Jiménez-Delgado JD
Rev Esp Quimioter; 2018 Aug; 31(4):374-375. PubMed ID: 30014680
[No Abstract] [Full Text] [Related]
37. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Castón JJ; De la Torre Á; Ruiz-Camps I; Sorlí ML; Torres V; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956431
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Buonomo AR; Maraolo AE; Scotto R; Foggia M; Zappulo E; Congera P; Parente S; Gentile I
Infection; 2020 Apr; 48(2):303-307. PubMed ID: 31981091
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and risk factors for mortality in children with Pseudomonas aeruginosa bacteraemia: A retrospective review at a paediatric tertiary centre.
Kishimoto K; Kasai M; Kawamura N; Otake S; Hasegawa D; Kosaka Y
J Paediatr Child Health; 2021 Dec; 57(12):1976-1980. PubMed ID: 34169605
[TBL] [Abstract][Full Text] [Related]
40. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.
Tofas P; Samarkos M; Piperaki ET; Kosmidis C; Triantafyllopoulou ID; Kotsopoulou M; Pantazatou A; Perlorentzou S; Poulli A; Vagia M; Daikos GL
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):335-341. PubMed ID: 28529091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
